Immuneering to Present at the Leerink Global Healthcare Conference
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) will present at the Leerink Global Healthcare Conference in Miami, March 9-11, 2026. CEO Ben Zeskind will deliver a fireside chat and hold 1x1 investor meetings on March 9, 2026, 3:40–4:10 pm ET.
The presentation will be webcast live and archived in the company's Investor Relations Events & Presentations section.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peer moves are mixed, with names like RCKT up 9.15% and others such as LRMR down 4.15%, suggesting stock-specific rather than sector-wide drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Investor conference | Positive | +4.4% | Oppenheimer healthcare conference presentation with webcast and 1x1 investor meetings. |
| Jan 07 | Clinical data update | Positive | -43.2% | Updated Phase 2a pancreatic cancer data showing strong 12-month survival metrics. |
| Jan 07 | Clinical data preview | Positive | +8.1% | Announcement of upcoming webcast to present 12‑month overall survival results. |
| Dec 17 | Phase 3 planning | Positive | +3.1% | Secured FDA and EMA alignment for global Phase 3 MAPKeeper 301 trial design. |
| Dec 16 | Index inclusion | Positive | -0.7% | Expected addition to the Nasdaq Biotechnology Index prior to December 22, 2025. |
Past conference and index-related news often saw modest moves, while major clinical data sometimes produced sharp, even negative, reactions.
Over the last few months, Immuneering has transitioned from index recognition to pivotal clinical planning. In December 2025, the company advanced its Phase 3 MAPKeeper 301 trial design with FDA and EMA alignment and noted cash funding into 2029. Subsequent updates included strong Phase 2a pancreatic cancer survival data on January 7, 2026 and multiple investor conference appearances, such as Oppenheimer on February 25–26, 2026. Today’s Leerink conference participation continues this pattern of investor outreach and pipeline visibility.
Regulatory & Risk Context
An effective Form S-3 shelf filed on August 13, 2025 registers up to $300,000,000 of securities, including an equity distribution agreement covering up to $100,000,000 of Class A common stock. The shelf has seen 2 usage events via Form 424B5, indicating the company has an established mechanism for raising capital as needed.
Market Pulse Summary
This announcement highlights continued investor outreach, with Immuneering presenting its pipeline and strategy at the Leerink Global Healthcare Conference from March 9–11, 2026. It follows recent clinical and regulatory milestones and adds another webcasted forum for management to update investors. With an existing $300,000,000 shelf and prior use of equity distribution, investors may watch for any capital‑raising steps, alongside progress of the MAPKeeper 301 Phase 3 program and further survival data updates.
AI-generated analysis. Not financial advice.
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Leerink Global Healthcare Conference, taking place in Miami, Florida, from March 9-11, 2026. Ben Zeskind, Chief Executive Officer, will discuss the company’s pipeline, platform, and business strategy.
Format: Fireside Chat and 1x1 Investor Meetings
Date/Time: Monday, March 9, 2026, from 3:40 – 4:10 pm ET
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and early-stage programs. For more information, please visit www.immuneering.com.
Investor Contact:
Courtney Dugan
Cdugan@immuneering.com
Media Contact:
Gina Nugent
Gina.nugent.external@immuneering.com
FAQ
When will Immuneering (IMRX) present at the Leerink Global Healthcare Conference?
How can investors watch Immuneering's (IMRX) Leerink conference presentation?
Who will represent Immuneering (IMRX) at the Leerink Global Healthcare Conference?
What topics will Immuneering (IMRX) cover during the March 9, 2026 presentation?
Where and when is the Leerink Global Healthcare Conference that features Immuneering (IMRX)?
